Catriona Yale Sells 9,073 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 9,073 shares of the firm’s stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $37.91, for a total value of $343,957.43. Following the sale, the insider now owns 95,034 shares in the company, valued at $3,602,738.94. This trade represents a 8.72 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Catriona Yale also recently made the following trade(s):

• On Monday, March 17th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $44.76, for a total value of $447,600.00.
• On Wednesday, March 12th, Catriona Yale sold 614 shares of Akero Therapeutics stock. The shares were sold at an average price of $44.88, for a total value of $27,556.32.
• On Tuesday, February 18th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $49.87, for a total transaction of $498,700.00.

Akero Therapeutics Trading Up 0.5 %

Shares of AKRO opened at $37.63 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics, Inc. has a 12 month low of $17.86 and a 12 month high of $58.40. The stock has a market cap of $3.00 billion, a PE ratio of -10.03 and a beta of -0.18. The stock’s 50-day moving average is $43.52 and its two-hundred day moving average is $36.06.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.01). Equities analysts forecast that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. RTW Investments LP increased its stake in Akero Therapeutics by 15.9% during the 4th quarter. RTW Investments LP now owns 6,859,823 shares of the company’s stock worth $190,840,000 after buying an additional 940,388 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Akero Therapeutics by 13.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,321,972 shares of the company’s stock valued at $120,238,000 after buying an additional 513,613 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Akero Therapeutics by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 3,704,411 shares of the company’s stock valued at $103,057,000 after acquiring an additional 27,830 shares in the last quarter. Deep Track Capital LP increased its position in shares of Akero Therapeutics by 116.0% during the fourth quarter. Deep Track Capital LP now owns 1,490,000 shares of the company’s stock worth $41,452,000 after acquiring an additional 800,216 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of Akero Therapeutics by 93.3% in the first quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company’s stock worth $46,786,000 after acquiring an additional 557,794 shares in the last quarter.

Analyst Ratings Changes

AKRO has been the subject of several research analyst reports. Canaccord Genuity Group upped their price target on shares of Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. Citigroup upped their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $35.00 to $63.00 in a research report on Thursday, January 30th. Morgan Stanley reissued an “overweight” rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Finally, HC Wainwright raised their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Monday, March 3rd. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $76.29.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.